VRNA Stock Summary and Trading Ideas (Verona Pharma PLC - American Depositary Shares | NASDAQ:VRNA)

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

Verona Pharma PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol VRNA.

As of April 25, 2024, VRNA stock price climbed to $15.31 with 481,310 million shares trading.

VRNA has a beta of 1.25, meaning it tends to be more sensitive to market movements. VRNA has a correlation of 0.09 to the broad based SPY ETF.

VRNA has a market cap of $1.24 billion. This is considered a Small Cap stock.

Last quarter Verona Pharma PLC - American Depositary Shares reported $0 in Revenue and -$.18 earnings per share. This met revenue expectation and exceeded earnings estimates by $.08.

In the last 3 years, VRNA stock traded as high as $26.44 and as low as $3.41.

The top ETF exchange traded funds that VRNA belongs to (by Net Assets): IBB, SBIO, GWX, ONEQ, GINN.

VRNA has underperformed the market in the last year with a price return of -33.4% while the SPY ETF gained +23.6%. VRNA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -9.9% and -5.9%, respectively, while the SPY returned +4.1% and -2.1%, respectively.

VRNA support price is $14.82 and resistance is $15.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRNA stock will trade within this expected range on the day.